Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Int J Drug Policy. 2022 Apr 10;104:103683. doi: 10.1016/j.drugpo.2022.103683

Table 1.

Baseline participant characteristics (N = 121).

Variable Not on MMT
N = 94 (%)
On MMT
N = 27 (%)
p-valuea
Sex 1.000
  Male 86 (91.5) 25 (92.6)
  Female 8 (8.5) 2 (7.4)
Age, mean ± SD (range) 34.4 ± 7.4 (21, 57) 38.2 ± 8.4 (25, 64) 0.021*
Marital Status 0.592
  Partnered 33 (35.1) 11 (40.7)
  Not partnered 61 (64.9) 16 (59.3)
Education 0.691
  Secondary or less 87 (92.6) 24 (88.9)
  Beyond secondary 7 (7.4) 3 (11.1)
Pre-incarceration Housing 0.702
  Own residence (rent/own) 17 (18.1) 5 (18.5)
  Friend or Relative’s home 71 (75.5) 19 (70.4)
  Other 6 (6.4) 3 (11.1)
Overdose in the 6 months before incarceration 0.782
  Yes 17 (18.1) 4 (14.8)
  No 77 (81.2) 23 (85.2)
Injected nearly daily in last 30 days before incarceration 0.004*
  Yes 19 (20.2) 13 (48.2)
  No 75 (79.8) 14 (51.8)
HIV Screening 0.730
  Positive 11 (11.7) 2 (7.4)
  Negative 83 (88.3) 25 (92.6)
Hepatitis B Surface Antigen 0.782
  Positive 17 (18.1) 4 (14.8)
  Negative 77 (81.2) 23 (85.2)
Hepatitis C Screening 0.004*
  Positive 40 (42.6) 7 (25.9)
  Negative 54 (57.4) 20 (74.1)
Syphilis (RPR) 0.682
  Positive 7 (7.4) 1 (3.7)
  Negative 87 (92.6) 26 (96.3)
Major Depression (CESD-10) 0.544
  Yes 46 (48.9) 15 (55.6)
  No 48 (51.1) 12 (44.4)
a

p-value from t-test for continuous variables and Fischer’s Exact or χ2 test for categorical variables.